Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience
Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…Dyskinesia and bradykinesia severity patterns in Parkinson’s disease using a wearable sensor
Objective: To determine if dyskinesia and bradykinesia severity has a diurnal pattern in Parkinson’s disease (PD) using wearable sensor data. Background: Diurnal fluctuations in PD…A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease
Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…Real-life gait performance as a marker for motor fluctuations: the Parkinson@home Validation study
Objective: To assess the feasibility of using real-life gait performance derived from a single wearable as a marker for motor fluctuations in Parkinson’s disease (PD).…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study
Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease
Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens
Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 26
- Next Page »